Analyst unconvinced by non-stimulants' current ADHD prospects

Stimulants, amphetamines and methylphenidates continue to dominate the attention deficit hyperactivity disorder (ADHD) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, UK and Japan), serving as the primary pharmacological treatment.

There may have been historical hesitancy towards their use in children but recent safety reassurances have increased acceptance.

The late-stage ADHD pipeline, meanwhile, introduces non-stimulant options with a focus on lower abuse potential. However, penetrating the stimulant-dominated market remains challenging without comparable efficacy, according to GlobalData, the data and analytics company.